Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Assets: 2016-2025

Historic Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Assets fell 22.62% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $1.5 billion for FY2024, which is 0.83% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Assets of $1.2 billion as of Q3 2025, which was down 8.87% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Assets registered a high of $1.6 billion during Q3 2022, and its lowest value of $1.2 billion during Q3 2025.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Assets value was $1.3 billion (recorded in 2025), while the average stood at $1.4 billion.
  • Its Assets has fluctuated over the past 5 years, first increased by 29.57% in 2021, then fell by 23.50% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Assets (Quarterly) stood at $1.5 billion in 2021, then increased by 1.51% to $1.5 billion in 2022, then decreased by 3.52% to $1.5 billion in 2023, then climbed by 0.83% to $1.5 billion in 2024, then fell by 22.62% to $1.2 billion in 2025.
  • Its Assets stands at $1.2 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.